NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Kymera Therapeutics, Inc. KYMR
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$39.2M
▼ 16.7% vs FY2024
EPS · FY25
$-3.69
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-25.8%
Net margin · FY25
-794.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 39.2M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 794 cents on every revenue dollar this year.
Per share
USD -3.69
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-25.8%
Return on equity, FY2025
ROE
Operating margin-891.1%
Net margin-794.0%
Return on assets-22.9%
Each USD of equity lost 26 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+2.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−5.7%
+2.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.08B
Shares outstanding, FY2025
Change, 5 years+82.8%
Change, 10 years—
The share count grew 83% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.7B
total assets, end of FY2025
Total assetsUSD 1.7B
EquityUSD 1.6B
CashUSD 357.0M
Current ratio10.47×
Equity funds 91% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.1
0.0
0.1
0.0
0.0
Operating income $B
−0.3
−0.3
−0.2
−0.2
−0.1
−0.0
−0.0
EBITDA $B
−0.3
−0.3
−0.2
−0.2
−0.1
−0.0
−0.0
Income tax $B
0.0
·
·
0.0
0.0
0.0
0.0
Net income $B
−0.3
−0.2
−0.1
−0.2
−0.1
−0.0
−0.0
EPS, diluted $
−3.69
−2.98
−2.52
−2.87
−2.09
−3.15
−24.28
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−25.8
−36.4
−33.2
−32.6
−27.0
−43.5
·
Shares out B
0.08
0.06
0.06
0.06
0.05
0.04
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed